Literature DB >> 25994198

Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement.

Arun Chockalingam1, Rafael Duran2, Jae Ho Sohn3, Rüdiger Schernthaner4, Julius Chapiro5, Howard Lee6, Sonia Sahu7, Sonny Nguyen8, Jean-François Geschwind9, MingDe Lin10.   

Abstract

OBJECTIVES: To investigate the influence of region-of-interest (ROI) placement on 3D tumour enhancement [Quantitative European Association for the Study of the Liver (qEASL)] in hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE).
METHODS: Phase 1: 40 HCC patients had nine ROIs placed by one reader using systematic techniques (3 ipsilateral to the lesion, 3 contralateral to the lesion, and 3 dispersed throughout the liver) and qEASL variance was measured. Intra-class correlations were computed. Phase 2: 15 HCC patients with histosegmentation were selected. Six ROIs were systematically placed by AC (3 ROIs ipsilateral and 3 ROIs contralateral to the lesion). Three ROIs were placed by 2 radiologists. qEASL values were compared to histopathology by Pearson's correlation, linear regression, and median difference.
RESULTS: Phase 1: The dispersed method (abandoned in phase 2) had low consistency and high variance. Phase 2: qEASL correlated strongly with pathology in systematic methods [Pearson's correlation coefficient = 0.886 (ipsilateral) and 0.727 (contralateral)] and in clinical methods (0.625 and 0.879). However, ipsilateral placement matched best with pathology (median difference: 5.4 %; correlation: 0.89; regression CI: [0.904, 0.1409]).
CONCLUSIONS: qEASL is a robust method with comparable values among tested placements. Ipsilateral placement showed high consistency and better pathological correlation. KEY POINTS: Ipsilateral and contralateral ROI placement produces high consistency and low variance. Both ROI placement methods produce qEASL values that correlate well with histopathology. Ipsilateral ROI placement produces best correlation to pathology along with high consistency.

Entities:  

Keywords:  Hepatocellular carcinoma; MRI; ROI; TACE; Tumour segmentation

Mesh:

Substances:

Year:  2015        PMID: 25994198      PMCID: PMC4654989          DOI: 10.1007/s00330-015-3812-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Abdomen: diffusion-weighted MR imaging with pulse-triggered single-shot sequences.

Authors:  Petra Mürtz; Sebastian Flacke; Frank Träber; Johan S van den Brink; Jürgen Gieseke; Hans H Schild
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

3.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

Review 4.  Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.

Authors:  Scott B Reeder; Irene Cruite; Gavin Hamilton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2011-09-16       Impact factor: 4.813

5.  Unbiased ROI selection in neuroimaging studies of individual differences.

Authors:  Roberto Viviani
Journal:  Neuroimage       Date:  2009-11-06       Impact factor: 6.556

6.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Chung-Mau Lo; Henry Ngan; Wai-Kuen Tso; Chi-Leung Liu; Chi-Ming Lam; Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

Review 7.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

8.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

9.  Comparison of test-injection method and fixed-time method for depiction of hepatocellular carcinoma using dynamic steady-state free precession magnetic resonance imaging.

Authors:  Kenji Shinozaki; Kengo Yoshimitsu; Hiroyuki Irie; Hitoshi Aibe; Tsuyoshi Tajima; Akihiro Nishie; Tomohiro Nakayama; Daisuke Kakihara; Mitsuo Shimada; Hiroshi Honda
Journal:  J Comput Assist Tomogr       Date:  2004 Sep-Oct       Impact factor: 1.826

10.  The importance of AIF ROI selection in DCE-MRI renography: reproducibility and variability of renal perfusion and filtration.

Authors:  M Cutajar; I A Mendichovszky; P S Tofts; I Gordon
Journal:  Eur J Radiol       Date:  2009-06-21       Impact factor: 3.528

View more
  16 in total

1.  Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?

Authors:  Yan Zhao; Rafael Duran; Wei Bai; Sonia Sahu; Wenjun Wang; Sven Kabus; MingDe Lin; Guohong Han; Jean-François Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2017-10-30       Impact factor: 2.740

2.  The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma.

Authors:  Susanne Smolka; Julius Chapiro; Wilfred Manzano; John Treilhard; Eric Reiner; Yanhong Deng; Yan Zhao; Bernd Hamm; James S Duncan; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind
Journal:  Clin Imaging       Date:  2017-06-07       Impact factor: 1.605

3.  Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.

Authors:  Vania Tacher; MingDe Lin; Rafael Duran; Hooman Yarmohammadi; Howard Lee; Julius Chapiro; Michael Chao; Zhijun Wang; Constantine Frangakis; Jae Ho Sohn; Mitchell Gil Maltenfort; Timothy Pawlik; Jean-François Geschwind
Journal:  Radiology       Date:  2015-07-01       Impact factor: 11.105

4.  Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?

Authors:  Sonia Sahu; Ruediger Schernthaner; Roberto Ardon; Julius Chapiro; Yan Zhao; Jae Ho Sohn; Florian Fleckenstein; MingDe Lin; Jean-François Geschwind; Rafael Duran
Journal:  Radiology       Date:  2016-11-10       Impact factor: 11.105

5.  Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis.

Authors:  Milena Miszczuk; Julius Chapiro; Duc Do Minh; Johanna Maria Mijntje van Breugel; Susanne Smolka; Irvin Rexha; Bruno Tegel; MingDe Lin; Lynn Jeanette Savic; Kelvin Hong; Christos Georgiades; Nariman Nezami
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-08       Impact factor: 2.797

6.  Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.

Authors:  Lucas C Adam; Lynn J Savic; Julius Chapiro; Brian Letzen; MingDe Lin; Christos Georgiades; Kelvin K Hong; Nariman Nezami
Journal:  Clin Imaging       Date:  2022-06-26       Impact factor: 2.420

7.  Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.

Authors:  Tabea Borde; Nariman Nezami; Fabian Laage Gaupp; Lynn Jeanette Savic; Tamar Taddei; Ariel Jaffe; Mario Strazzabosco; MingDe Lin; Rafael Duran; Christos Georgiades; Kelvin Hong; Julius Chapiro
Journal:  Radiology       Date:  2022-04-12       Impact factor: 29.146

8.  Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.

Authors:  Aaron Abajian; Nikitha Murali; Lynn Jeanette Savic; Fabian Max Laage-Gaupp; Nariman Nezami; James S Duncan; Todd Schlachter; MingDe Lin; Jean-François Geschwind; Julius Chapiro
Journal:  J Vasc Interv Radiol       Date:  2018-03-14       Impact factor: 3.464

9.  3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.

Authors:  Florian N Fleckenstein; Rüdiger E Schernthaner; Rafael Duran; Jae Ho Sohn; Sonia Sahu; Yan Zhao; Bernd Hamm; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind; Julius Chapiro
Journal:  Eur Radiol       Date:  2016-01-13       Impact factor: 5.315

10.  Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.

Authors:  Brian S Letzen; Rohil Malpani; Milena Miszczuk; Quirina M B de Ruiter; Christopher W Petty; Irvin Rexha; Nariman Nezami; Fabian Laage-Gaupp; MingDe Lin; Todd R Schlachter; Julius Chapiro
Journal:  Clin Imaging       Date:  2021-05-18       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.